Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.2K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

832
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
832
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

381
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
381
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

186
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
186
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same author

LINC00607 facilitates endothelial VEGF-A receptor FLT1 splicing.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Downregulation of the Long Non-Coding RNA <i>KLRK1-AS1</i> Disturbs Endothelial Barrier Integrity and Promotes Angiogenic Sprouting.

Life (Basel, Switzerland)·2026
Same author

Loss of Myonuclei and Transcriptional Activity During Diaphragm Atrophy in Critically Ill Patients.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.

Cardiovascular research·2025
Same author

Leukocytes use endothelial membrane tunnels to extravasate the vasculature.

Cell reports·2025

Related Experiment Video

Updated: Dec 28, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.6K

RNA-based therapeutics in cardiovascular disease.

Tan Phát Pham1, Veerle Kremer1,2, Reinier A Boon1,3,4

  • 1Department of Physiology, Amsterdam Cardiovascular Sciences, Vrije Universiteit, Amsterdam UMC location Vumc.

Current Opinion in Cardiology
|February 19, 2020
PubMed
Summary
This summary is machine-generated.

RNA-based therapeutics offer novel treatments for cardiovascular disease. Research is advancing RNA molecules and delivery methods to overcome challenges and improve patient outcomes.

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.9K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.2K

Related Experiment Videos

Last Updated: Dec 28, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.6K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.9K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.2K

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Therapeutics

Background:

  • Cardiovascular disease is a leading global cause of mortality, necessitating innovative treatment strategies.
  • RNA molecules play critical roles in disease development and progression, presenting therapeutic opportunities.

Purpose of the Study:

  • To review RNA-based therapeutics for cardiovascular disease.
  • To examine current clinical and preclinical studies of RNA-based treatments.
  • To discuss challenges and solutions for clinical translation of RNA therapies.

Main Methods:

  • Review of different classes of RNA-based therapeutic molecules (e.g., antisense oligos, microRNA mimics, small interfering RNAs).
  • Discussion of chemical modifications to enhance RNA stability and reduce immunogenicity.
  • Exploration of viral and nonviral vector systems for targeted RNA delivery.

Main Results:

  • Various RNA-based molecules have been developed with specific modifications for improved properties.
  • Delivery systems, including vectors, are being employed to enhance tissue targeting of RNA therapeutics.
  • Clinical and preclinical studies demonstrate the potential of RNA-based therapies.

Conclusions:

  • RNA-based therapy is a promising strategy for various disorders, including cardiovascular disease.
  • Key challenges include optimizing delivery to target tissues and enhancing therapeutic efficacy.
  • Future research will focus on overcoming these hurdles to improve treatment outcomes and minimize side effects.